A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 EFFICACY STUDY OF AN AD26.RSV.PREF-BASED VACCINE IN THE PREVENTION OF LOWER RESPIRATORY TRACT DISEASE CAUSED BY RSV IN ADULTS AGED 60 YEARS AND OLDER

Registry ID
VAC18193RSV3001
Source registry
HEALTH_CANADA
Status
Closed
Phase
PHASE3
Study type
INTERVENTIONAL
Sponsor
JANSSEN VACCINES & PREVENTION B.V.
Start date
2022-06-07
Completion date
2023-03-29
Last update
2021-07-23

Conditions

Related clinical trials

View on source registry